This clinical trial is investigating a treatment for patients with metastatic non-small-cell lung cancer. The main treatment being studied is called LN-145, which consists of special immune cells called tumor-infiltrating lymphocytes that are taken from the patient’s own tumor tissue. These cells are processed in a laboratory and then given back to the patient through an intravenous infusion.

Before receiving LN-145, patients will undergo treatment with other medications to prepare their body. These medications include fludarabine, cyclophosphamide, and aldesleukin. The fludarabine is given for 5 days, followed by cyclophosphamide for 2 days, and then the LN-145 cells are infused. After the cell infusion, patients receive aldesleukin to help support the transferred cells.

The purpose of this study is to determine if LN-145 therapy is effective in treating metastatic non-small-cell lung cancer by measuring how many patients respond to the treatment. The study will also evaluate how safe the treatment is and how long the treatment effects last. Patients will be monitored for side effects and their response to therapy throughout the study period.